Page 212 - 2020_02-Haematologica-web

B. Maurer et al.
here represents a tool to investigate molecular mecha- nisms of PTCL development. Our model serves for identi- fication and pre-clinical testing of novel interventional strategies to target STAT5-dependent PTCL. We conclude that both STAT5A and STAT5B are oncogenes in PTCL, and STAT5B is more transforming. Overall, mutation induced-cytokine sensitivity drives PTCL due to enhanced STAT3/STAT5 signaling.
Acknowledgments
Jerry Adams (WEHI, Australia) kindly provided us with the
vav-hCD4 (HS21/45) plasmid and Dagmar Stoiber (LBI-CR, Vienna, Austria) with the E.G7 cell line. We thank Safia Zahma (LBI-CR, Vienna, Austria), Elisabeth Gurnhofer, Sigurd Krieger (both at the Department of Clinical Pathology, Medical University Vienna, Austria), Sabine Fajmann (Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria), and Boris Kovacic (Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria) for technical support. We thank also our mouse facility team and Jisung Park (Department of Chemistry, University of Toronto Mississauga, Canada) for synthesizing the inhibitor AC-3-19 used in this study.
References
1. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756-6767.
2. Armitage JO. The aggressive peripheral T- cell lymphomas: 2017. Am J Hematol. 2017;92(7):706-715.
3. Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecu- lar and clinical features. Blood. 2014;123(19):3007-3015.
4. SiaghaniPJ,SongJY.UpdatesofperipheralT cell lymphomas based on the 2017 WHO classification. Curr Hematol Malig Rep. 2018;13(1):25-36.
5. Laginestra MA, Piccaluga PP, Fuligni F, et al. Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified. Blood Cancer J. 2014;4(11):259.
6. IqbalJ,WrightG,WangC,etal.Geneexpres- sion signatures delineate biological and prog- nostic subgroups in peripheral T-cell lym- phoma. Blood. 2014;123(19):2915-2923.
7. IqbalJ,WeisenburgerDD,GreinerTC,etal. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognos- tication in angioimmunoblastic T-cell lym- phoma. Blood. 2010;115(5):1026-1036.
8. HeinrichT,RengstlB,MuikA,etal.Mature T-cell lymphomagenesis induced by retrovi- ral insertional activation of Janus kinase 1. Mol Ther. 2013;21(6):1160-1168.
9. Warner K, Crispatzu G, Al-Ghaili N, et al. Models for mature T-cell lymphomas—a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts. Crit Rev Oncol Hematol. 2013;88(3):680-695.
10. SpinnerS,CrispatzuG,YiJH,etal.Re-acti- vation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia. 2016;30(7):1520-1530.
11. Piccaluga P, Tabanelli V, Pileri S. Molecular genetics of peripheral T-cell lymphomas. Int J Hematol. 2014;99(3):219-226.
12. Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique sub- group of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741- 1752.
13. Wilcox RA. A three-signal model of T-cell lymphoma pathogenesis. Am J Hematol. 2016;91(1):113-122.
14. Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47 (11):1304-1315
15. Schrader A, Crispatzu G, Oberbeck S, et al.
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018;9(1):697.
16. Litvinov IV, Tetzlaff MT, Thibault P, et al. Gene expression analysis in cutaneous T-cell lymphomas (CTCL) highlights disease het- erogeneity and potential diagnostic and prognostic indicators. Oncoimmunology. 2017;6(5):e1306618-e1306618.
17. Warner K, Weit N, Crispatzu G, Admirand J, Jones D, Herling M. T-cell receptor signaling in peripheral T-cell lymphoma – a review of patterns of alterations in a central growth regulatory pathway. Curr Hematol Malig Rep. 2013;8(3):163-172.
18. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
19. Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Novel insights into the pathogenesis of T-cell lymphomas. Blood. 2018;131 (21):2320-2330.
20. Lone W, Alkhiniji A, Manikkam Umakanthan J, Iqbal J. Molecular insights into pathogenesis of peripheral T cell lym- phoma: a review. Curr Hematol Malig Rep. 2018;13(4):318-328.
21. Coppe A, Andersson EI, Binatti A, et al. Genomic landscape characterization of large granular lymphocyte leukemia with a sys- tems genetics approach. Leukemia. 2017;31 (5):1243-1246.
22. Koskela HLM, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905-1913.
23. Rajala HLM, Eldfors S, Kuusanmäki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121(22):4541-4550.
24. Bandapalli OR, Schuessele S, Kunz JB, et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica. 2014;99(10):e188-e192.
25. Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolympho- cytic leukemia. Blood. 2014;124(9):1460- 1472.
26. Kontro M, Kuusanmaki H, Eldfors S, et al. Novel activating STAT5B mutations as puta- tive drivers of T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(8):1738-1742.
27. Nicolae A, Xi L, Pittaluga S, et al. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia. 2014;28(11):2244- 2248.
28. Küçük C, Jiang B, Hu X, et al. Activating
mutations of STAT5B and STAT3 in lym- phomas derived from γδ-T or NK cells. Nat Commun. 2015;6:6025
29. Kiel MJ, Sahasrabuddhe AA, Rolland DCM, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome. Nat Commun. 2015;6:8470.
30. Dufva O, Kankainen M, Kelkka T, et al. Aggressive natural killer-cell leukemia muta- tional landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018;9(1):1567.
31. Cross NCP, Hoade Y, Tapper WJ, et al. Recurrent activating STAT5B N642H muta- tion in myeloid neoplasms with eosinophil- ia. Leukemia. 2018;33(2):415–425.
32. Pham HTT, Maurer B, Prchal-Murphy M, et al. STAT5B(N642H) is a driver mutation for T cell neoplasia. J Clin Invest. 2018;128(1):387-401.
33. Heltemes-Harris LM, Farrar MA. The role of STAT5 in lymphocyte development and transformation. Curr Opin Immunol. 2012;24(2):146-152.
34. Hoelbl A, Kovacic B, Kerenyi MA, et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transfor- mation. Blood. 2006;107(12):4898-4906.
35. Ermakova O, Piszczek L, Luciani L, et al. Sensitized phenotypic screening identifies gene dosage sensitive region on chromo- some 11 that predisposes to disease in mice. EMBO Mol Med. 2011;3(1):50-66.
36. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph- like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
37. Moriggl R, Sexl V, Kenner L, et al. Stat5 tetramer formation is associated with leuke- mogenesis. Cancer Cell. 2005;7(1):87-99.
38. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoim- mune disease. Curr Opin Pharmacol. 2012; 12(4):464-470.
39. Cumaraswamy AA, Lewis AM, Geletu M, et al. Nanomolar-potency small molecule inhibitor of STAT5 protein. ACS Med Chem Lett. 2014;5(11):1202-1206.
40. Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compart- ment. Blood. 1999;94(6):1855-1863.
41. Berard M, Tough DF. Qualitative differences between naïve and memory T cells. Immunology. 2002;106(2):127-138.
42. Krishnan L, Gurnani K, Dicaire C, et al. Rapid clonal expansion and prolonged main- tenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central
446
haematologica | 2020; 105(2)